NCT02972905View on ClinicalTrials.gov

Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

GSK2269557 ELLIPTA DPI

GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister and 500 mcg per blister.

DRUG

Placebo ELLIPTA DPI

Placebo ELLIPTA DPI contains lactose

Trial Locations (1)

813-0017

GSK Investigational Site, Fukuoka

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02972905 - Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy Subjects | Biotech Hunter | Biotech Hunter